Pfizer posts better-than-expected Q2 earnings and sales, raises 2025 EPS outlook, and outlines $7.7 billion in cost-saving initiatives through 2027.
Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook
Where Today's News Shapes Tomorrow
